ALZHEIMER'S FOUNDATION OF AMERICA

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$1.8M

Filings

Firms Hired

Active Period

2004–2022

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2022	$133,000	4	1
2021	$178,500	4	1
2020	$170,500	4	1
2019	$165,000	4	1
2018	$147,500	4	1
2017	$120,500	4	1
2016	$116,500	4	1
2015	$112,600	4	1
2014	$109,000	4	1
2013	$130,500	5	1
2012	$113,000	5	1
2011	$78,750	4	1
2010	$47,500	4	1
2009	$90,000	4	1
2008	$66,250	10	2
2007	$12,000	6	2
2006	—	2	1
2005	—	1	1
2004	—	2	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ALZHEIMER'S FOUNDATION OF AMERICA	$1,791,100	65
SQUIRE PATTON BOGGS	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	69
HOUSE OF REPRESENTATIVES	68
Health & Human Services, Dept of (HHS)	59
Administration on Aging	53
Office of Management & Budget (OMB)	38
White House Office	36
Natl Institutes of Health (NIH)	22
Centers For Medicare and Medicaid Services (CMS)	20
Food & Drug Administration (FDA)	12
Justice, Dept of (DOJ)	5
President of the U.S.	2
Vice President of the U.S.	2
Housing & Urban Development, Dept of (HUD)	1
Labor, Dept of (DOL)	1
Social Security Administration (SSA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Budget/Appropriations	Budget/Appropriations	75
Health Issues	Health Issues	73
Medicare/Medicaid	Medicare/Medicaid	49
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	21
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	12
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	3
Pharmacy	Pharmacy	3
Retirement	Retirement	2
Labor Issues/Antitrust/Workplace	Labor Issues/Antitrust/Workplace	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1474117th Congress

Alzheimer's Caregiver Support Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: H.R. 1474

H.R. 2517117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: H.R. 2517

H.R. 2517117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: H.R. 2517

H.R. 3085117th Congress

ENACT Act of 2021

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: H.R.3085

Show 21 more cited filings

H.R. 3354117th Congress

CHANGE Act of 2021

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: H.R.3354

H.R. 7775117th Congress

NAPA Reauthorization Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: H.R. 7775

S. 1125117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: S.1125

S. 1125117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: S. 1125

S. 1548117th Congress

ENACT Act of 2021

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: S.1548

S. 1692117th Congress

Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $43,000 · Firm income: —

Matched citations: S.1692

S. 4203117th Congress

NAPA Reauthorization Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: S. 4203

S. 56117th Congress

Alzheimer's Caregiver Support Act

2022 · third_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; FY 2023 Continuing Resolution S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $43,000 · Firm income: —

Matched citations: S. 56

H.R. 1474117th Congress

Alzheimer's Caregiver Support Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: H.R. 1474

H.R. 2517117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: H.R. 2517

H.R. 2517117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: H.R. 2517

H.R. 3085117th Congress

ENACT Act of 2021

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: H.R.3085

H.R. 3354117th Congress

CHANGE Act of 2021

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: H.R.3354

H.R. 7775117th Congress

NAPA Reauthorization Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: H.R. 7775

S. 1125117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: S.1125

S. 1125117th Congress

Comprehensive Care for Alzheimer’s Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: S. 1125

S. 1548117th Congress

ENACT Act of 2021

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: S.1548

S. 1692117th Congress

Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies

Client expense: $45,000 · Firm income: —

Matched citations: S.1692

S. 4203117th Congress

NAPA Reauthorization Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: S. 4203

S. 56117th Congress

Alzheimer's Caregiver Support Act

2022 · second_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2023 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act S. 4203/H.R. 7775, the Reauthorization of NAPA Act

Client expense: $45,000 · Firm income: —

Matched citations: S. 56

H.R. 1474117th Congress

Alzheimer's Caregiver Support Act

2022 · first_quarter · Firm: ALZHEIMER'S FOUNDATION OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

FY 2022 Appropriations for HHS; S. 56/H.R. 1474, the Alzheimer's Caregiver Support Act H.R. 2517/S.1125 Comprehensive Care for Alzheimer's Act

Client expense: $45,000 · Firm income: —

Matched citations: H.R. 1474

Source: Senate LDA

ALZHEIMER'S FOUNDATION OF AMERICA — Lobbying Disclosure | Poliscope